TY - JOUR
T1 - Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation
AU - Ashley Moseman, E.
AU - Wu, Tuoqi
AU - de la Torre, Juan Carlos
AU - Schwartzberg, Pamela L.
AU - McGavern, Dorian B.
N1 - Funding Information:
We would like to thank J. Pickel and the NIMH Transgenic Core Facility for their assistance in generating the new transgenic GCaMP6s reporter mice. We also want to acknowledge D. Maric and the National Institute of Neurological Disorders and Stroke Sorting Facility for assistance. This research was supported by the intramural program at the NIH.
Publisher Copyright:
2016 © The Authors.
PY - 2016
Y1 - 2016
N2 - Studies have established a role for T cells in resolving persistent viral infections, yet emerging evidence indicates that both T and B cells are required to control some viruses. During persistent infection, a marked lag or failure to generate neutralizing antibodies is commonly observed and likely contributes to an inability to control certain pathogens. Using lymphocytic choriomeningitis virus (LCMV) as a model, we have examined how a persistent viral infection can suppress neutralizing humoral immunity. By tracking the fate of virus-specific B cells in vivo, we report that LCMV-specific B cells were rapidly deleted within a few days of persistent infection, and this deletion was completely reversed by blockade of type I interferon (IFN-I) signaling. Early interference with IFN-I signaling promoted survival and differentiation of LCMV-specific B cells, which accelerated the generation of neutralizing antibodies. This marked improvement in antiviral humoral immunity did not rely on the cessation of IFN-I signaling in B cells but on alterations in the virus-specific CD8+ T cell response. Using two-photon microscopy and in vivo calcium imaging, we observed that cytotoxic T lymphocytes (CTLs) productively engaged and killed LCMV-specific B cells in a perforin-dependent manner within the first few days of infection. Blockade of IFN-I signaling protected LCMV-specific B cells by promoting CTL dysfunction. Therapeutic manipulation of this pathway may facilitate efforts to promote humoral immunity during persistent viral infection in humans. Our findings illustrate how events that occur early after infection can disturb the resultant adaptive response and contribute to viral persistence.
AB - Studies have established a role for T cells in resolving persistent viral infections, yet emerging evidence indicates that both T and B cells are required to control some viruses. During persistent infection, a marked lag or failure to generate neutralizing antibodies is commonly observed and likely contributes to an inability to control certain pathogens. Using lymphocytic choriomeningitis virus (LCMV) as a model, we have examined how a persistent viral infection can suppress neutralizing humoral immunity. By tracking the fate of virus-specific B cells in vivo, we report that LCMV-specific B cells were rapidly deleted within a few days of persistent infection, and this deletion was completely reversed by blockade of type I interferon (IFN-I) signaling. Early interference with IFN-I signaling promoted survival and differentiation of LCMV-specific B cells, which accelerated the generation of neutralizing antibodies. This marked improvement in antiviral humoral immunity did not rely on the cessation of IFN-I signaling in B cells but on alterations in the virus-specific CD8+ T cell response. Using two-photon microscopy and in vivo calcium imaging, we observed that cytotoxic T lymphocytes (CTLs) productively engaged and killed LCMV-specific B cells in a perforin-dependent manner within the first few days of infection. Blockade of IFN-I signaling protected LCMV-specific B cells by promoting CTL dysfunction. Therapeutic manipulation of this pathway may facilitate efforts to promote humoral immunity during persistent viral infection in humans. Our findings illustrate how events that occur early after infection can disturb the resultant adaptive response and contribute to viral persistence.
UR - http://www.scopus.com/inward/record.url?scp=84997122944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84997122944&partnerID=8YFLogxK
U2 - 10.1126/sciimmunol.aah3565
DO - 10.1126/sciimmunol.aah3565
M3 - Article
C2 - 27812556
AN - SCOPUS:84997122944
SN - 2470-9468
VL - 1
JO - Science Immunology
JF - Science Immunology
IS - 4
M1 - eaah3565
ER -